Multiple Myeloma · Active Clinical Trials
As of 2026-09-04, the full China registry snapshot contains 70 active multiple myeloma interventional trials across 31 provincial-level regions and 338 China study centres, see landscape index. The list below provides peer-reviewed published English translations and can be filtered by modality, target, phase, and province.
Notice for International Patients
These records are provided for research-information purposes. An English summary does not mean that the clinical trial accepts international patients. Eligibility, language requirements, residence requirements and long-term follow-up must be confirmed directly with the clinical trial team. Original registry filings remain in Chinese. For a non-trial route, see independent guide to CAR-T in China.
Trial Decision Guides
All trial FAQsNotice for Patients on Stable Therapy:If your current regimen is effective, do not discontinue standard treatment. Clinical trial matching is recommended upon documented disease progression.
Found 8 matching clinical trials
View CAR-T LandscapeA Phase I Study of In Vivo CAR-T Therapy for Advanced Malignant Tumors (Multiple Myeloma, Lymphoma, Leukemia, Solid Tumors)
Locations & Centers
Cancer Hospital, Chinese Academy of Medical Sciences
Target / Modality
In situ (in vivo) CAR-T cell therapy targeting multiple targets including BCMA/GPRC5D/DLL3/FcRH5
A Phase II, open-label, single-arm, multicenter clinical study evaluating the efficacy and safety of BCMA-targeted chimeric antigen receptor T-cell injection (CART-BCMA) in patients with relapsed/refractory multiple myeloma (RRMM)
Locations & Centers
The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Beijing Jishuitan Hospital 等 25 家
Target / Modality
BCMA-targeted chimeric antigen receptor T-cell (CAR-T) therapy
A Phase I Clinical Study of CBG002 CAR-T Cell Injection in Patients with Relapsed or Refractory Multiple Myeloma
Locations & Centers
The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Sun Yat-sen University Cancer Center
Target / Modality
BCMA-targeting CAR-T cell therapy
A Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of CR-2011 in Relapsed/Refractory Multiple Myeloma
Locations & Centers
Cancer Hospital Chinese Academy of Medical Sciences
Target / Modality
In vivo chimeric antigen receptor T-cell (CAR-T) therapy targeting BCMA (based on mRNA-LNP technology)
An Early Exploratory Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of BCMA/GPRC5D Dual-Targeted Allogeneic Universal CAR-T Cell Injection (DQ1001) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Locations & Centers
Zhongshan Hospital, Xiamen University
Target / Modality
Allogeneic universal CAR-T targeting BCMA/GPRC5D
An Early Exploratory Clinical Study of the Safety and Efficacy of KSVCBD Injection in the Treatment of CD19- and/or BCMA-Positive B-Cell Malignancies
Locations & Centers
Chinese PLA General Hospital (301 Hospital)
Target / Modality
CD19, BCMA
An Open-Label, Multicenter Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of OriCAR-017 in Participants with Relapsed/Refractory Multiple Myeloma (MERCURY)
Locations & Centers
The First Affiliated Hospital, Zhejiang University School of Medicine、Shanghai Tongji Hospital、Jiangsu Province Hospital 等 8 家
Target / Modality
GPRC5D-targeted CAR-T
In Vivo-Generated PICX Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Locations & Centers
The 920th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army
Target / Modality
BCMA/CD70 CAR-T